跳轉至內容
Merck
全部照片(1)

文件

45706

Supelco

华法林

PESTANAL®, analytical standard

同義詞:

4-羟基-3-(3-氧代-1-苯基丁基)-2H-1-苯并吡喃-2-酮, 杀鼠灵钠

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C19H16O4
CAS號碼:
分子量::
308.33
Beilstein:
8868198
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

analytical standard

品質等級

產品線

PESTANAL®

儲存期限

limited shelf life, expiry date on the label

技術

HPLC: suitable
gas chromatography (GC): suitable

mp

162-164 °C (lit.)

應用

agriculture
environmental

格式

neat

SMILES 字串

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI 密鑰

PJVWKTKQMONHTI-UHFFFAOYSA-N

基因資訊

human ... VKORC1(79001)

尋找類似的產品? 前往 產品比較指南

相關類別

應用

华法林是一种常用于预防血栓形成和血栓栓塞的抗凝剂。 其已在许多中风和肺纤维化患者研究中使用。 它已用于研究潜在风险以及与其他药物和食物的相互作用
有关合适的仪器技术的更多信息,请参阅产品的分析证书。想要获得更多支持,请联系技术服务部。

生化/生理作用

华法林由两种活性对映体R和S形式的外消旋混合物组成。 华法林比普通抗凝肝素作用慢。 华法令可抑制钙依赖性凝血因子II、VII、IX和X的生物活性形式的维生素K依赖性合成。它可抑制调节因子蛋白C、蛋白S和蛋白Z

注意

仅限于专业用户。注意 — 避免接触 — 使用前请阅读说明书。

法律資訊

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

標靶器官

Blood

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 2

1 of 2

Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation.
Jeffrey I Weitz et al.
Circulation, 129(16), 1688-1694 (2014-04-23)
Daisuke Yoshioka et al.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 17(4), 308-314 (2014-07-23)
The aim of this study was to evaluate our clinical experience with the Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New York, NY, USA), a miniature axial flow left ventricular assist device (LVAD). The clinical results of eight patients
Aaron Liew et al.
The Canadian journal of cardiology, 29(7 Suppl), S34-S44 (2013-06-29)
Warfarin is effective for the prevention and treatment of thromboembolism but produces variable anticoagulant effects and requires routine monitoring of the international normalized ratio (INR) to optimize the balance between efficacy and safety. The new oral anticoagulants (NOACs) have a

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務